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Abstract
Background: The OPTI-SCRIPT cluster randomised controlled trial (RCT) found that a three-phase multifaceted
intervention including academic detailing with a pharmacist, GP-led medicines reviews, supported by web-based
pharmaceutical treatment algorithms, and tailored patient information leaflets, was effective in reducing potentially
inappropriate prescribing (PIP) in Irish primary care. We report a process evaluation exploring the implementation of
the intervention, the experiences of those participating in the study and lessons for future implementation.
Methods: The OPTI-SCRIPT trial included 21 GP practices and 196 patients. The process evaluation used mixed
methods. Quantitative data were collected from all GP practices and semi-structured interviews were conducted
with GPs from intervention and control groups, and a purposive sample of patients from the intervention group. All
interviews were transcribed verbatim and analysed using a thematic analysis.
Results: Despite receiving a standardised academic detailing session, intervention delivery varied among GP
practices. Just over 70 % of practices completed medicines review as recommended with the patient present. Only
single-handed practices conducted reviews without patients present, highlighting the influence of practice
characteristics and resources on variation. Medications were more likely to be completely stopped or switched to
another more appropriate medication when reviews were conducted with patients present. The patient information
leaflets were not used by any of the intervention practices. Both GP (32 %) and patient (40 %) recruitment rates
were modest. For those who did participate, overall, the experience was positively viewed, with GPs and patients
referring to the value of medication reviews to improve prescribing and reduce unnecessary medications. Lack of
time in busy GP practices and remuneration were identified as organisational barriers to future implementation.
Conclusions: The OPTI-SCRIPT intervention was positively viewed by both GPs and patients, both of whom valued
the study’s objectives. Patient information leaflets were not a successful component of the intervention. Academic
detailing and medication reviews are important components in changing PIP, and having patients present during
the review process seems to be a more effective approach for decreasing PIP.
Trial registration: Current controlled trials ISRCTN41694007. Registered on 21 March 2012.
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Background
Potentially inappropriate prescribing (PIP) comprises a
number of suboptimal prescribing practices, including
inappropriate dose or duration of medication, drug–drug
interactions, drug–disease interactions, and use of medi-
cations that have a significant risk of an adverse drug
event (ADE) [1]. Recent systematic reviews report an esti-
mated PIP prevalence of 20 % in community-dwelling
patients [2, 3]. PIP has become an important public health
concern as patients with PIP have been found to have a
more than twofold increased odds of experiencing adverse
drug reactions [4] and a nearly a twofold increased risk in
the expected rate of emergency room visits [5]. PIP is also
associated with increased health expenditure [6, 7].
Decreasing the prevalence of PIP may have important
public health and financial benefits, particularly in pri-
mary care, where the majority of prescribing occurs.
However, to date, no single interventional strategy has
proven to be most effective [8–11].
The OPTImizing PreSCRIbing for Older People in Pri-
mary Care, a clusTer randomised controlled trial (OPTI-
SCRIPT) cluster randomised controlled trial (RCT)
demonstrated that a multifaceted intervention was ef-
fective in reducing PIP in primary care. The intervention
worked principally on reducing proton pump inhibitor
prescribing and appeared less effective on other classes
of PIP drugs such as long-term benzodiazepine pre-
scribing and therapeutic duplication [12]. The detailed
methods and results have been published elsewhere
[12–14]. In brief, the intervention involved academic
detailing with a pharmacist on conducting General Practi-
tioner (GP)-led medicines review with participating pa-
tients; medicines reviews were supported by web-based
pharmaceutical treatment algorithms for GPs, providing
evidence-based alternative treatment options to PIP drugs,
and tailored patient information leaflets (PILs). A sum-
mary of the study is presented in Appendix 1.
Process evaluations are recommended to contextualise
RCT results, answering key questions about why an inter-
vention has failed or succeeded and how it was imple-
mented [15]. Process evaluations are particularly relevant
to complex, multifaceted interventions such as OPTI-
SCRIPT. Such interventions involve multiple targets (for
example, patients and clinicians) and various active com-
ponents and are often criticised as their complexity makes
it difficult to measure their effects [16, 17]. To date, sys-
tematic guidance on what data a process evaluation
should collect and report has been lacking and process
evaluations have been planned and conducted in an ad
hoc fashion [18]. Grant et al., recently developed a frame-
work to guide the design and conduct of process evalua-
tions specifically for cluster RCTs [19]. The framework
presents a range of approaches to understanding trial de-
livery, intervention implementation, and the responses of
targeted participants, taking into consideration evaluation
at both the cluster and the individual participant level.
This paper presents the process evaluation conducted
as part of the OPTI-SCRIPT trial and aims to explore
how the intervention was implemented, the experiences
of those participating in the study and lessons for future
implementation.
Methods
The process evaluation undertaken used a mixed methods
approach, combining both qualitative and quantitative
data. The process evaluation framework outlined by Grant
et al. [19] was used to report the overall findings.
This study was approved by the research ethics commit-
tee of the Irish College of General Practitioners (ICGP)
and informed consent was given by all GP practices and
patients.
Study population
The OPTI-SCRIPT study was conducted in the Irish pri-
mary care setting (see Appendix 2) among patients aged
70 years and over as the prevalence of PIP is high in this
age group (36 % in 2007 [20]). Out of 21 GP practices,
11 practices (99 patients) were allocated to the interven-
tion group and 10 practices (97 patients) were allocated
to the control group using minimisation (Fig. 1).
Qualitative sampling
The lead GP in all of the 21 GP practices was asked to
participate in qualitative interviews with 17 agreeing, 13
(76.4 %) of whom were male. For patient interviews, only
those who experienced the intervention were invited to
participate (as questions mainly related to the experience
of intervention). Purposive sampling was used to ensure
coverage across GP practices and heterogeneity in terms
of patient gender, type of PIP drugs, outcome of medica-
tion review. Out of 14 patients approached in the inter-
vention group, 11 patients agreed to participate in an
interview. Fifty-four percent of patient interviewees were
male compared to 53.5 % of non-interviewees. The aver-
age age of interviewees was 78 years compared to 77 for
non-interviewees.
Data collection
Quantitative data were compiled from a number of
sources. First, all GP practices completed a practice char-
acteristics form upon recruitment, providing details on
numbers of staff, location and numbers of patients. Sec-
ond, all participating patients completed a questionnaire
providing basic demographic details, health service utilisa-
tion and patient-reported outcome measures. Third, the
OPTI-SCRIPT study team maintained researcher logs of
the recruitment process and all contacts with participants.
Finally, in the intervention group, process measure data
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were collected by evaluation forms, which were integrated
into the web-based pharmaceutical treatment algorithms.
These forms were completed by GPs upon completion of
each OPTI-SCRIPT medication review.
Qualitative data were collected using semi-structured
interviews. Intervention group patients (n = 11) were
interviewed within 1 month of undertaking the OPTI-
SCRIPT medicines review and intervention group GPs
(n = 7) were interviewed within 1 month of completion of
the final OPTI-SCRIPT medicines review for that practice.
Control group GPs (n = 10) were interviewed upon final
data collection conducted at intervention completion. In-
terviews were conducted by a single interviewer (BC) ei-
ther in person or via telephone. Telephone interviewing is
generally used where time or costs are issues, and evi-
dence suggests there is little difference in the answers ob-
tained this way [21, 22]. All interviews were audio
recorded (on loud speaker for telephone interviews). The
semi-structured GP interview topic guide was used to fa-
cilitate discussion of common prescribing-related issues in
older patients and experiences of trial participation such
as problems with the study processes or intervention and
improvements which could be made. The patient topic
guide focused on patients’ perceptions of their medica-
tions and their experiences of the medication review
process (Appendix 3). Patient interviews lasted an average
of 11.6 minutes (min 6.2–max 20.3), while GP interviews
lasted an average of 14.5 minutes (min 8.56–max 26.31).
Fig. 1 Flow of practices and patients through the study. *Eligibility fraction: Proportion of potential participants who undergo screening and are
eligible to enrol. ‘Recruitment fraction: Proportion of potential participants who actually enrol in the RCT. ^Enrolment fraction: Proportion of
people who are eligible for participation and who actually enrol in the RCT. ~Number of patients needed to be screened: Number of patients
screened in order to randomise one participant (1/recruitment fraction). Source: adapted from Gross et al. 2002 [50]
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Data analysis
Quantitative data were inputted into STATA Version 13
(StataCorp, College Station, TX, USA) and summarised
using descriptive statistics.
All interviews were audiotaped and transcribed verba-
tim. A thematic analysis was performed using a ‘top down’
approach to coding [23], using the pre-defined categories
of the Grant et al. framework as overarching themes [19].
Familiarisation with data was achieved through reading
and re-reading transcripts one by one in detail. Field notes
and observations were not used in the analysis. Initial
codes were generated from commonly occurring patterns
and were grouped into potential sub-themes and related
directly to the pre-determined framework. Quotations
were used as exemplars of key themes.
NVivo 10 was used to assist with organising the data
for analysis. All transcripts were reviewed independently
by two researchers (BC, JAC) and the findings discussed
to confirm the validity of the emerging results. All par-
ticipant data were pseudo-anonymized by assignment of
a unique study ID.
Results
The results are summarised in Table 1.
Recruitment of practices
A total of 65 eligible GP practices from 88 in the HRB
Centre for Primary Care Research practice network were
invited (by email with follow-up phone call) to partici-
pate. No national register of GPs exists in Ireland so this
network offered a convenient sample of GPs to contact.
The area was restricted to greater Dublin to facilitate the
academic detailing process. Initially, 26 practices agreed
to participate but five practices withdrew prior to patient
recruitment1 and practice randomisation, due to time
constraints, meaning a total of 21 practices (32.3 %) par-
ticipated (Fig. 1). Of the 39 practices who declined to
participate, the majority (54 %) did so as the practice
was too busy (Fig. 1). In contrast to a national sample
(Table 2), participating study practices were slighter lar-
ger in terms of the average number of GPs and General
Medical Services (GMS) patient lists, and were all in-
volved in undergraduate/postgraduate teaching.
Delivery to practices
All intervention practices received the same, standar-
dised intervention. Practices participated in an academic
detailing session with a research pharmacist in their own
practice (lasting approximately 30 minutes). This in-
volved a brief presentation on PIP and a practical com-
ponent on how to use the web-based pharmaceutical
treatment algorithms for the review of medications,
using simulated patients, and a dummy username and
password for the website. Each GP received Continuing
Medical Education (CME) points for participating in the
academic detailing session, which are necessary for
Table 1 Summary of methods and findings of the OPTI-SCRIPT process evaluation
Domain Research focus Data source Main findings
Recruitment of practices How were practices sampled
and recruited?
Reasons for non-participation?
Study team recruitment logs Practices recruited from the HRB primary care research
network by email with follow-up call.
Recruitment modest, main reason for declining was
practice being too busy.
Delivery to practices What intervention is delivered
for each practice?
Is it the one intended by
the researchers?
Semi-structured interviews Academic detailing delivered to intervention practices
as planned.
Letters sent to control practices as planned.
Response of practices How is the intervention
adopted by clusters?
Website activity, semi-structured
interviews
Medication reviews conducted as planned by eight
(73 %) intervention practices, two (18 %) conducted
reviews without patients present.
Two (20 %) control practices made changes to patients.
Recruitment and reach
in individuals
Who actually receives the
intervention in each setting?
Are they representative?
Study team recruitment logs,
patient questionnaire data
Patients recruited broadly similar to national population
demographically.
Delivery to individuals Who received medication
reviews?
Semi-structured interviews,
website activity
Eighty-six patients had reviews, one practice conducted
no reviews.
How were reviews
conducted?
Semi-structured interviews Eight intervention practices conducted reviews with
patients, two practices conducted reviews without
patients present.
What were the outcomes
of the reviews?
Website activity Most common outcome – dose reduction.
Responses of individuals How does the target
population respond?
Semi-structured interviews Patients happy to participate and valued the opportunity
to review unnecessary medication.
Source: adapted from Grant et al. 2013 [19]
Abbreviations: OPTI-SCRIPT OPTImizing PreSCRIbing for Older People in Primary Care, a cluster randomised controlled trial, HRB Health Research Board
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ongoing registration with the national regulatory body.
The academic detailing was described by the majority of
GPs (9/10) as “straightforward” (GP16, intervention
practice), and “very useful” (GP18, intervention practice).
The research pharmacist reported that the GPs were re-
ceptive to the study objectives.
The control group practices were mailed simple feed-
back, outlining the participating patients and the particular
category of PIP that applied to them. They were not en-
couraged to conduct medicines reviews or given any tools
to support conducting reviews.
Response of practices: how the intervention was adopted
Intervention group practices
Of the 11 practices in the intervention group, eight
(73 %) conducted medicines reviews with the participat-
ing patients present web-based pharmaceutical treat-
ment algorithms as outlined in the academic detailing
(adoption as planned), two practices (18 %) conducted
the reviews using the web-based pharmaceutical treat-
ment algorithms in the absence of the patients and one
practice (9 %) did not complete any medicines reviews.
Where reviews were conducted without patients present
(adaptation), GPs made notes in the patient charts regard-
ing any changes to specified medication(s). One practice
did not undertake face-to-face reviews with patients by
choice. The second practice conducted the reviews with-
out patients present due to study time constraints. Both
were single-handed practices and the GPs were confident
that their patients would accept the changes:
“I think it’s probably easier in this practice because it is
single-handed. Ok, you know, it’s not like I’m changing
something that one of my colleagues put them on and
said to them, you must stay on this or whatever, they all
deal with me, for better or worse – I don’t know!” (GP21,
intervention practice).
While practices differed in terms of conducting reviews
with and without patients present, all practices (10/10) were
consistent in terms of a second adaptation and the use of
the PILs. The PILs were not used as part of the review
process in the intervention group. In the main, GPs forgot
to provide patients with the PILs and indicated that in this
patient group, such extra material was not necessary:
“I didn’t have to, you know, the whole process is that
our patients, if they trust us, and we explain
everything to them, what we are doing, em, you don’t
need to, we don’t need to do that [give PILs].” (GP16,
intervention practice).
When asked if they would have liked to receive the
PILs, generally this patient group reported not having
much use for such materials:
“Oh no, no, I don’t welcome those sorts of things; they just
pile up here in the house.” (P13.47, intervention patient).
The majority (9/10) of practices conducted reviews
as patients presented for their repeat prescription, as
recommended in the study protocol. However, one
Table 2 Comparison of OPTI-SCRIPT participating practices and
patients to national populations
Characteristic Study participants National population
GP practice
Practice type
GMS and private 100 % 96.0 %a
GMS list size
500 or less 14.3 % 29.8 %b
501–1500 23.8 % 59.6 %b
1501–2500 61.9 % 10.6 %b
Practice staff
Single-handed GP 14.3 % 35.0 %a
2+ GPs 85.7 % 65.0 %a
Practice manager 71.4 % 30.0 %a
Practice location
Urban 76.2 % 43.0 %a
Mixed 23.8 % 36.0 %a
Teaching activity 100 % 42.0 %a
Patients
Total population
Male 105 (53.6 %) 157,016 (43.4 %)c
Age category
70–75 94 (48.5 %) 154,286 (42.6 %)c
76–80 58 (29.7 %) 95,894 (26.5 %)c
81–85 35 (17.9 %) 63,406 (17.5 %)c
86–90 6 (3.1 %) 34,358 (9.5 %)c
91 and over 2 (1.0 %) 13,811 (3.8 %)c
Marital status
Married 107 (54.9 %) 170,560 (47.1 %)c
Single 24 (12.3 %) 55,371 (15.3 %)c
Widowed 58 (29.7 %) 125,551 (34.7 %)c
Divorced 3 (1.5 %) 3,767 (1.0 %)c
Separated 2 (1.0 %) 6,506 (1.8 %)c
GMS card holder 183 (93.4 %) 360,000 (96.0 %)b
Abbreviations: OPTI-SCRIPT OPTImizing PreSCRIbing for Older People in Primary
Care, a cluster-randomised controlled trial, GP General Practitioner, GMS General
Medical Services
Sources:
aO’Dowd et al. [51]
bPrimary Care Reimbursement Service report 2011, Table 10 [52]
cCensus of Population 2011
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practice contacted the patients to attend a specific
consultation outside of the repeat prescription time-
line. Conducting the reviews with the patients was
described positively by all GPs:
“Oh yeah, it was very good, yeah, because actually,
because they were coming in you were able to look at
everything properly and they were coming in a structured
review … just to give you a time to review the whole
situation you know, in regards to all of their prescribing.
It was very useful, yeah.” (GP18, intervention practice).
The reviews were a positive experience for two main
reasons. First, the intervention website and treatment al-
gorithms were considered simple and easy to engage
with by all GPs:
“It was very straightforward, it worked well I thought,
em it was clear and you know, from our point of view,
actually when you actually got down to it, the patient,
the actual process of going through the patient was
quite quick.” (GP24, intervention practice).
Second, the majority of GPs (8/10) reported that patients
were overall “very receptive” (GP16, intervention practice)
to the review process, making the consultation a positive
and rewarding encounter from the GP perspective:
“I actually think that this study has made me review
my patients more closely, so I think it’s good for me
personally, which means it’s good for my patients in
the end.” (GP23, intervention practice).
Despite being asked to conduct all reviews within 6–8
weeks and receiving weekly reminder emails and calls,
there were significant differences in the time between
academic detailing and completion of all reviews by inter-
vention practices (minimum 3 weeks, maximum 28 weeks)
(Fig. 2). Longer completion times generally reflected a lack
of resources to dedicate to the study within the practice:
“That was difficult, because, the person who manages
such things is [practice nurse], who was on sick leave
for most of the study. So there was nobody driving the
process because [practice nurse] was away, we had
only very little nursing cover in her absence, then we
were doing tasks that would have been previously done
by the nurse, so it was a very busy time.” (GP7,
intervention practice).
Control group practices
The majority of the control group (80 %) reported that
they did very little with the feedback letter provided to
them. However, two GPs (20 %) reported that the simple
feedback prompted them to change medications that
may have been a concern to them (adaptation):
“What I did was, I went in to all the files and I did a
mail merge and wrote to them and changed their
meds. So basically, there was a PPI - reduce the dose
by half, so I just did that immediately and told them
that I did that and why.” (GP3, control practice).
Recruitment and reach of individuals (patients)
Patient identification and recruitment was carried out by
GP practices prior to practice randomisation as the
study team did not have access to patient contact details
or records until they consented to participate. This
process was time-consuming and significant delays were
introduced where GP practice staff were required to be
Fig. 2 Time (weeks) from academic detailing to intervention practices completing all medicines reviews
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involved (Appendix 4). Overall, patient identification and
recruitment was reported as being quite onerous and was
considered “…the only graft” (GP16, intervention practice)
involved in participating in the study by many of the GPs.
Recruitment burden was a source of frustration and an-
noyance for many of the GPs (7/10) and some had not an-
ticipated the extra work it would involve:
“I resented the reminders … I had underestimated the
amount of involvement it would require from the practice.
That’s what I would say.” (GP7, intervention practice).
A total of 1306 patients were screened, 492 (38 %) of
whom were found to be eligible and invited to partici-
pate. In total, 196 consented to participate, giving an
overall response rate (enrolment fraction) of 40 %. Over-
all, six people needed to be screened in order to ran-
domise one patient (Fig. 1). Recruited patients were
demographically similar to the general population of
those aged 70 and over in Ireland (Table 2).
Delivery to individuals (patients)
Review outcomes
A total of 86 (87 %) reviews were conducted out of a po-
tential 99; ten (10 %) were not conducted as one practice
completed no reviews and three (3 %) were not con-
ducted as the patient was deceased or withdrew. During
the 86 medication reviews, 114 potentially inappropriate
prescriptions were assessed. Of these, 44 (39 %) pre-
scriptions were not altered, for reasons including the
prescription being initiated in hospital (n = 10), patient
preference (n = 9) and lack of available alternatives. The
62 remaining inappropriate prescriptions were altered,
with the majority of changes (n = 30, 48 %) made in the
form of a dose reduction, reflecting the fact that the ma-
jority of these changes were reductions in the use of pro-
ton pump inhibitors at maximum therapeutic dose.
Analysis of the OPTI-SCRIPT RCT data highlighted
that the effectiveness of the intervention overall was
largely mediated through a reduction in the prescribing
of proton pump inhibitors with no statistically signifi-
cant effect on other types of potentially inappropriate
medicines such as long-term use of benzodiazepines.
Some GPs were sceptical about the benefits of discon-
tinuation of such medications in older patients:
“Sometimes, for example, in relation to benzodiazepine,
em, you know, somebody might be on benzodiazepines
and has been for 40 years, which one of the patients
actually was, I don’t think it’s appropriate to stop that.
If they’re stable and they can get on with their lives then
I think it would cause more hassle for them.” (GP1,
intervention practice).
However, out of 14 prescriptions of long-term benzo-
diazepine in the intervention group, five (36 %) were al-
tered while the remaining nine (64 %) were unaltered
due to patient preference.
Of the reviews conducted, 67 (78 %) were conducted with
the patient present and 19 (22 %) were conducted without
the patient present. A total of 89 potentially inappropriate
prescriptions were assessed during reviews with patients
present compared to 25 potentially inappropriate prescrip-
tions in reviews conducted without patients present. Al-
though the numbers are small, differences in the changes
made to PIP drugs during reviews conducted with and with-
out patients present were observed (Fig. 3) with a higher
proportion of reviews conducted with patients present
resulting in a complete removal of the medication (22 %)
compared to reviews without the patients (4 %). Switching
to alternative, more appropriate medications was also more
common when the patient was present at the review (9 %
compared to 4 %). Practices who conducted reviews without
the patient present were all single-handed practices.
Fig. 3 Comparison of changes to PIP drugs during medicines reviews conducted with and without patients present
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Response of individuals (patients) to the medicines
review process
All patients interviewed reported that medicines reviews
were a good idea and regardless of whether or not changes
were made to their medication regimen, patients were re-
ceptive to the idea as “nobody wants to take more medica-
tions than they need to”. (P13.45, intervention patient).
Overall, patients’ responses to the medication review
process were classified across the themes of benefits and
barriers (Table 3). Benefits of the reviews included a percep-
tion of receiving high-quality care for the majority of pa-
tients (7/11), providing reassurance that their health and
well-being was a priority. The review provided an oppor-
tunity for patients to examine their medications as many
(6/11) recognised the potential to be taking medications
that may no longer be necessary. Two patients reflected on
the wider societal implications of taking medications that
may no longer be clinically necessary as wasteful. Both
highlighted that by reducing waste in this area, there may
be the potential to save money that could be redistributed
in other areas. However, despite the overall positive views
on the medication reviews, a number of patients highlighted
that GP time and workload were a barrier (Table 3).
Future implementation: GP perspective
The future implementation of an intervention to assist
with conducting medication reviews was mainly viewed
as a positive aspiration. GPs from both intervention and
control groups expressed a desire to learn and a willing-
ness to change their prescribing practices:
“When you are a GP you get practices and you get bad
habits, and you get good habits, and sometimes you
are too busy to change your habits until it is pointed
out so, anything like this is a good thing.” (GP19,
control practice).
Patients also perceived the value of the objectives of the
medication review process and expressed support for the
opportunity to stop unnecessary medications. Despite this
enthusiasm, GPs did not seem to consider this as part of
their current core work, and a number of organisational
barriers to the provision of medicines reviews as standard
in Irish primary care in the future were identified, particu-
larly in relation to workload and reimbursement.
GPs highlighted that current workloads made dedi-
cated reviews for all older patients unfeasible due to
time constraints:
“General practice at the moment now, as far as I can
see, is getting hit by about 30 % more extra work, due
to the economic downturn, so most medical card list
have gone up by about 30 %, and that is increasing a
huge volume of work, because those patients before,
happened to be in the non-medical card area and
they weren’t consulting as much. So they are now
consulting, eh, much more frequently so it’s very
little time left … if you had to do that every
6 months, to review all those patients. Where would
you get the time?” (GP5 control practice).
Solutions offered by GPs to this workload problem
included the use of alerts embedded into practice man-
agement systems and involving pharmacists in the medi-
cation review process. A number of GPs highlighted that
focusing on a select number of high-risk or “cardinal
PIPs” would make the process more manageable:
“I think that if you keep it simple, and maybe in a
structured way if you could layer it, so that you know,
for 2012 we are focusing on these five issues and in
2013 we’re focusing on these, you know. There would
be a little bit of slippage with last year’s issues, but
over time you would introduce better prescribing.”
(GP13, intervention practice).
Reimbursement within the current structures was also
highlighted as a barrier. At present, the majority of pa-
tients aged 70 years and older are General Medical Ser-
vices (GMS) patients and as such, access the GP free at
the point of use. GPs are reimbursed via capitation by
the state. GPs highlighted that there may be resistance
from both patients and the government to paying extra
for a medicines review consultation.
“I often wonder if the government was to pay a fee for
us to review ten patients every 3 months formally, but
they’re going to say, we’re already paying you to do
these prescriptions, to write these prescriptions you
know, like come on guys, and they are right.” (GP13,
intervention practice).
“Unless it’s free they won’t come in and even if it is free, I
don’t know, it’s difficult to get them in you know. Em, if
they are paying, definitely they won’t want to come in to
do something that they think is for your benefit and not
for theirs you know.” (GP18, intervention practice).
Discussion
This process evaluation combined qualitative and quantita-
tive methods to enhance understanding of the implementa-
tion of the OPTI-SCRIPT intervention, the experiences of
those participating in the study, and lessons for future
implementation.
Intervention implementation
The results demonstrate that there was variation in
how the intervention components were delivered by
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Table 3 OPTI-SCRIPT process evaluation: themes and supporting quotes
Main theme Sub-theme Example quote
Delivery to practices Academic detailing quality “Yes, that was very informative, very straightforward, very user friendly.” (GP16, intervention
practice)
Response of
intervention group
Adoption as planned “O yeah, it was very good, yeah, because actually, because they were coming in you
were able to look at everything properly and they were coming in a structured
review .... .just to give you a time to review the whole situation you know, in regards
to all of their prescribing. It was very useful, yeah.” (GP18, intervention practice).
Adaptation
I. Reviews without
patients
“So I didn’t do it with the patients but what I did was, I think you saw from the patient records,
I highlighted the notes on it, and I’d have put tags on charts when I found, yeah that needs to
be done, to be addressed with their next prescription. (GP21, intervention practice).
II. Patient information
leaflet non-use
“I didn’t have to, you know, the whole process is that our patients, if they trust us, and we
explain everything to them, what we are doing, em, you don’t need to, we don’t need to
do that [give PILs].” (GP16, intervention practice).
Facilitators of
implementation
I. Simplicity
“It was very straightforward, it worked well I thought, em it was clear and you know,
from our point of view, actually when you actually got down to it, the patient, the
actual process of going through the patient was quite quick.” (GP24, intervention practice).
II. Patient receptivity “Absolutely no problem at all. And in fact, if anything they were quite glad, you know, that
somebody is looking at their medications and making sure that it is OK, and all the rest.”
(GP1, intervention practice).
Barriers of implementation
I. Staff
“That was difficult, because, the person who manages such things is [practice nurse], who
was on sick leave for most of the study. So there was nobody driving the process because
[practice nurse] was away, we had only very little nursing cover in her absence, then
we were doing tasks that would have been previously done by the nurse, so it was a very
busy time.” (GP7, intervention practice).
Response of
control group
Adaptation “What I did was, I went in to all the files and I did a mail merge and wrote to them and
changed their meds. So basically, there was a PPI - reduce the dose by half, so I just did
that immediately and told them that I did that and why.” (GP3, control practice).
Recruitment and
reach in individuals
Recruitment burden “I resented the reminders … I had underestimated the amount of involvement it would
require from the practice. That’s what I would say” (GP7, intervention practice)
Responses of
individuals
Benefits of reviews
I. Quality of care
“I think it is important really, because it makes people feel, well, you know that there is
somebody that cares. You know, as you are getting older, that there is somebody that
cares about the elderly, that they, you know, are being properly looked after and people
are thinking about them.” P23.38
II. Societal good “I’m sure, I’m absolutely sure, there through not the patient’s fault, eh, there must be an
amazing amount of pharmaceutical waste consumed by patients who don’t really eh, need
it. And as you say, the purpose of your exercise is to find out if some of these can be
dropped. In fact, I’m sure they could be and, the monies saved by the State could eh, be
put into looking after the less fortunate people.” P1.61
III. Necessary medication “You’re inclined to go on things and be left on them and then you wonder should you be
on them all that time, is there any side effects with them, all that kinda thing.” P7.4
Barriers to reviews
I. GP workload
“Well, I mean, if my, if my GP has time to do that sort of thing then fine, you know.” P18.48
Future implementation Facilitators
I. Positive aspiration
“When you are a GP you get practices and you get bad habits, and you get good habits,
and sometimes you are too busy to change your habits until it is pointed out so, anything
like this is a good thing.” (GP19, control practice).
II. Cardinal PIPs “I think that if you keep it simple, and maybe in a structured way if you could layer it, so
that you know, for 2012 we are focusing on these five issues and in 2013 we’re focusing
on these, you know. There would be a little bit of slippage with last year’s issues, but over
time you would introduce better prescribing.” (GP13, intervention practice).
Barriers
I. Workload
“General practice at the moment now, as far as I can see, is getting hit by about 30 %
more extra work, due to the economic downturn, so most medical card list have gone
up by about 30 %, and that is increasing a huge volume of work, because those patients
before, happened to be in the non-medical card area and they weren’t consulting as
much. So they are now consulting, eh, much more frequently so it’s very little time
left … if you had to do that every 6 months, to review all those patients. Where would
you get the time?” (GP5, control practice).
II. Reimbursement “I often wonder if the government was to pay a fee for us to review ten patients every
3 months formally, but they’re going to say, we’re already paying you to do these
prescriptions, to write these prescriptions you know, like come on guys, and they are
right.” (GP13, intervention practice).
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GP practices despite receiving a standardised academic
detailing session. First, just over 70 % of practices com-
pleted medicines review as recommended with the patient
present. Medications were more likely to be completely
stopped or switched to another more appropriate medica-
tion when reviews were conducted with patients present.
Organisational factors such as resources and workload are
often reasons for variation in intervention delivery [24]. In
this case, practice characteristics may have been influential
as both practices who conducted reviews without patients
present were single-handed practices. Strong evidence
supports the active involvement of older people in their
primary care episodes to improve health outcomes
[25, 26]. While the effects of patient participation in
medication reviews are understudied [27], recent evi-
dence from the EMPOWER study highlights that in-
creasing older people’s participation in prescribing
decisions can result in the discontinuation of inappro-
priate benzodiazepines (risk difference 23 %, 95 % CI 14–
32 %) [28]. Although based on small numbers, our
findings, and those of the EMPOWER study, provide sup-
port for actively encouraging shared decision-making be-
tween older patients and primary care prescribers, even
for medications typically considered difficult to change
such as benzodiazepines. It could be argued that medica-
tions such as proton pump inhibitors are easier to alter
where time and resources are limited but the fact that
36 % of benzodiazepines were altered in the OPTI-
SCRIPT study would suggest otherwise. Second, the PILs
were not utilised by participating GPs. Evidence indi-
cates that PILs are promising tools in reducing anti-
biotic prescribing in primary care and that older
patients appreciate being provided with brief, clearly
written information leaflets in addition to information
from their doctor [29, 30]. Both GP and patient par-
ticipants in this study felt that PILs were unnecessary,
however, as the GPs reported forgetting this element
of the intervention, it could be argued that its im-
portance was not fully conveyed during the academic
detailing process.
The control group also varied in its behaviour, with
two practices implementing changes based on the feed-
back letter they received – a common finding in
prescribing-based RCTs [31]. This activity was the driv-
ing force for the changes noted in the control group in
the RCT analysis. The fact that only a small proportion
of the control group implemented changes reinforces
the evidence that less intensive feedback on prescribing
behaviour is generally not sufficient to impact on pre-
scribing practices [32, 33].
Overall, these findings are consistent with previous
studies that have highlighted that complex interventions
in primary care are often not implemented and utilised
as intended [34, 35].
Participant experience
Both GP (32 %) and patient (40 %) recruitment rates
were modest. The rates compare favourably to similar
PIP related RCTs [36], but smaller than reported in
other primary care studies [37]. For those GPs and pa-
tients who did take part, participation in the OPTI-
SCRIPT study was positively viewed. The intervention
was considered simple to engage with and the partici-
pants reported to agree in principle with the overall
study objectives (i.e. stopping or reducing unnecessary
medications in older patients). The OPTI-SCRIPT study
also provided the opportunity for altruism, and per-
ceived greater quality of care, important factors influen-
cing the participation of older people in RCTs [38]. For
GPs, the study provided the opportunity to improve care
for current patients, and update their knowledge and
clinical skills, commonly reported benefits of participa-
tion in research [39–41]. Volunteer bias may also pro-
vide an explanation for the overall positive experiences
reported. Those who volunteer for research studies may
be motivated by a particular interest in the study objective.
Comparison with a national sample of GPs highlighted
that OPTI-SCRIPT GPs may have been more research-
orientated but OPTI-SCRIPT patients’ demographics
reflected those of the general population.
GPs’ main critique of study participation related to pa-
tient recruitment, which is consistently one of the most
challenging aspects of research studies. The process of
identification and recruitment required more time than
expected, consistent with previous trials recruiting older
patients in primary care [42]. The numbers needed to
screen was six, meaning six people needed to be
screened in order to randomise one, larger than has
been reported in other primary care based studies (me-
dian 2.43 [37]). Workload and time remain significant
barriers to participation in such research by GPs. It is
important to minimise the efforts required by practice
staff to recruit patients [43]. In the UK, research net-
works such as The Clinical Research Network offer ser-
vices to assist with timely recruitment, however, in this
case, no such services operate and ethical committee re-
quirements were such that the burden of recruitment
fell heavily on the practices involved. Excessive delays,
variability in process and outcome, and imposed require-
ments that can have negative consequences for study
conduct are common challenges reported during the re-
search ethics review process for cluster RCTs [44]. In
the absence of support services, electronic identification
of potential participants could potentially expedite the
recruitment process.
Future implementation
The main RCT demonstrated that the OPTI-SCRIPT
intervention was effective in reducing PIP in primary
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care [12]. The challenge remains how to embed this type
of intervention within the current structures of health
care services. Rogers (2003) identified the key attributes
(as perceived by prospective adopters), that influence the
adoption of an intervention into practice [45]. Innova-
tions that are perceived as having greater relative advan-
tage (innovation is perceived as better than the idea it
supersedes), compatibility (agreement between the inno-
vation and organizational values and beliefs), simplicity
(degree of difficult to use), trialability (how much
innovation can be experimented with), and observability
(ease with which results can be seen) will be adopted
more rapidly than others. The process evaluation identi-
fied OPTI-SCRIPT as having relative advantage, com-
patibility, observability and was low in complexity.
Coupled with the predominantly positive experiences re-
ported during the process evaluation, this would suggest
that the implementation of such an intervention would
be acceptable to both GP and patient participants alike.
However, medicines reviews did not seem to be consid-
ered core work. Despite the enthusiasm expressed, there
was considerable variation in the time taken to complete
the reviews (3–28 weeks) and reminders from the study
team were required. In order to implement medicines
reviews as standard practice outside of the study setting,
the organisational barriers of GP workloads, time to
conduct the reviews, and reimbursement mechanisms
need to be considered. Focusing on a select number of
specific medications or “cardinal PIPs” offers a means to
decrease workload barriers.
Just under 40 % of potentially inappropriate prescrip-
tions were unaltered due to factors such as hospital initi-
ation, patient preference and lack of alternatives, serving
as a reminder that although a medication may be con-
sidered inappropriate for older people, it may still be
prescribed [46].
Strengths and limitations of this study
This study is one of a growing number of process evalu-
ations published independently of the main RCT find-
ings [15, 47, 48] and is one of first to adopt a process
evaluation framework explicitly intended for use in clus-
ter RCTs [19]. Quantitative and qualitative data were
systematically collected and rigorously analysed, provid-
ing an insight into patient and GP perspectives of the
intervention and its implementation.
A number of important findings emerged from the
qualitative data which would not have been evident from
the quantitative analyses such as the variation in con-
ducting reviews with and without patients present, re-
inforcing the important contribution that qualitative
methods can have in such evaluations [49]. However, the
limitations of this study lie primarily with the collection
of qualitative data as some participants were not
available for interview. In particular, the GP who did not
conduct any of the medication reviews was not inter-
viewed. The practice provided the OPTI-SCRIPT team ac-
cess to patient data, but attempts to schedule an interview
with the GP were unsuccessful. As the only GP not to
complete the reviews, this interview would have provided
some valuable insights. The GP indicated that although
the practice intended to conduct the reviews, they had no
time to complete the study. A further limitation to the
qualitative data may be the length of the interviews which
were an average of 15 minutes with GPs and 12 minutes
with patients which may have affected the richness of the
data collected; however, all items on the topic guide were
addressed.
Lessons learnt and future research
The valuable insights gained during this process evalu-
ation are summarised in Table 4. Based on these find-
ings, revisions to the intervention will be made and a
definitive trial with a larger sample size and longer
follow-up period will be conducted.
Conclusions
In summary, decreasing PIP in primary care is achiev-
able, particularly through involving older patients in
medication reviews. The OPTI-SCRIPT RCT and process
evaluation found that the intervention was effective, feas-
ible and was acceptable to GPs and older patients. How-
ever, PILs were not a successful component of the
intervention. Plans for wider implementation of the inter-
vention in primary care would need to increase support
for patient recruitment and address organisational barriers
to implementation such as lack of time in busy GP prac-
tices and remuneration.
Endnote
1All practice and patient baseline data was collected prior
to minimisation of practices to minimise selection bias.
Table 4 Insights/key messages from the OPTI-SCRIPT process
evaluation
• Complex interventions in primary care are often not implemented and
utilised as intended.
• Intervention delivery may vary by practice characteristics such as number
of GPs and practice resources.
• Recruitment continues to be one of the most challenging aspects of
conducting trials in primary care. In this setting, computerisation of
patient identification would decrease the requirements placed on GPs
at the start of the study and speed up the recruitment process.
• Involving patients in medication reviews has the potential to decrease
inappropriate prescribing.
• Targeting a smaller number of specific medication groups or “cardinal PIPs”
emerged as an important facilitator in overcoming workload barriers.
• Process evaluations are more informative when they incorporate both
qualitative and quantitative research methods.
Clyne et al. Trials  (2016) 17:386 Page 11 of 15
Appendix 1
Appendix 2 Appendix 3
Topic guide
Topic guide: GP
Broad prescribing-related interview questions
Could you tell me a little about your experience of
prescribing for your older patients?
Prompts: multimorbidity; polypharmacy; patient pref-
erence/demands
Are you familiar with the concept of PIP or the criteria
used to measure it, aside from this study?
Could you tell me a little about your perspective on
PIP? What is your view on PIP in primary care?
In your opinion, how is PIP important, relevant to
practice?
What is your opinion of the terminology used, PIP?
PIP as a concept
Are you familiar with the concept of PIP or the criteria
used to measure it, aside from this study?
Feelings about the concept in general:
 Could you tell me a little about your perspective on
PIP? What is your view on PIP in primary care?
 Feelings re the terminology
Table 5 Overview of the OPTI-SCRIPT cluster RCT methods and findings [11]
Aim To test the effectiveness of a multifaceted intervention in reducing the level of PIP in primary care.
Participants Twenty-one general practices (intervention n = 11, control n = 10).
A total of 196 patients ≥70 years (intervention n = 99, control group n = 97) with ≥1 PIP drugs.
Outcome measure Proportion of participant patients with PIP and the mean number of potentially inappropriate prescriptions per group.
Intervention group The intervention consisted of:
(1) Academic detailing with a pharmacist
One session (lasting 30 minutes) where a pharmacist visited the practice to discuss PIP, medicines review and the
web-based pharmaceutical treatment algorithms
(2) Medicines review with web-based pharmaceutical treatment algorithms. GPs were asked to conduct one review per
patient using the web-based platform to guide them through the process. The GP was presented with the specific
PIP drug(s) for each patient, and for each PIP drug, there was a treatment algorithm with the following structure:
a. The individual PIP with reason for concern
b. Alternative pharmacological and non-pharmacological treatment options
c. Background information (where relevant)
3) Patient information leaflets to give to patients during the review. Each leaflet:
a. Described the PIP and the reasons as to why it may be inappropriate
b. Outlined the alternative pharmacological and non-pharmacological therapies GPs may offer
Control group Control practices delivered usual care. Usual care for public General Medical Services (GMS) patients allows GPs to give a
prescription on a monthly or 3 monthly basis.
Control practices received simple patient-level PIP feedback in the form of a list summarizing the medication class to
which the individual patient’s potentially inappropriate medication belonged.
Control practices did not receive an academic detailing visit or were not prompted to carry out medicines review with
the individual patients.
Results Upon intervention completion:
• OPTI-SCRIPT intervention group had significantly lower odds of having PIP than control group (adjusted OR 0.32,
95 % CI 0.15 to 0.70, P < 0.01).
• Mean number of PIP drugs in the intervention group was 0.70, compared to 1.18 in the control group (P < 0.01).
• The intervention was effective in reducing proton pump inhibitor prescribing (adjusted OR 0.30, 95 % CI 0.14
to 0.68, P = 0.04).
Abbreviations: OPTI-SCRIPT OPTImizing PreSCRIbing for Older People in Primary Care, a clusTer randomised controlled trial, RCT randomised controlled trial, CI
confidence interval, GMS General Medical Services, PIP potentially inappropriate prescribing, OR odds ratio
Table 6 Key features of Irish Primary Care
• Mixed public private funding.
• No national register of GPs is in operation, but it is estimated that
there are approximately 2500 GPs in Ireland.
• Three categories of eligibility to primary health care:
○ Full eligibility: free access to primary health care via the
General Medical Services (GMS) scheme, which is means
tested. Prescription co-payments were introduced in 2010,
and amount to €2.50 per item, up to a maximum of €25
per family in 2014.
○ Limited eligibility: free access to GP visits but are required
to pay for all prescriptions up to a monthly limit of €144
per family.
○ Private patients: non-GMS patients are required to pay in
full for primary care services (approx. €50 per GP visit) and
are entitled to limited free public health services such as
maternity services and childhood immunisations.
Prescription costs are paid in full up to a monthly limit
of €144 per family.
• An estimated 97 % of people aged 70 and over qualify for the GMS
scheme.
• Standardised medication reviews for community-dwelling older
patients are not specifically recommended as is the case in the UK
with the National Service Framework for Older People.
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 In your opinion, how is it important, relevant to
practice?
For intervention GPs only
You had the AD session with the pharmacist and then
conducted the reviews with the patients
 What did you think of the AD session overall?
○ Trainer
○ Content
○ Information
○ Length
 Conducting the reviews – how do you feel the
process worked?
 Elements that worked
○ How was information incorporated in routine
practice?
○ How was helpful/unhelpful?
○ Information system, website, algorithm?
○ How did patients respond?
▪ Did you give them leaflets – feelings about them?
 Elements that may benefit from change
○ What was not helpful
○ Are there specific barriers to changes?
○ What could be done better?
 What would the ideal process look like to you?
 Can you comment on the time needed for this?
○ Longer than general consult, much preparation
involved?
 Making changes
○ Role of patient
○ Role of hospital
 Effects of intervention overall
 Overall, what was your experience of taking part in
this study?
For control GPs only
So now I would like to talk to you about what you did during
the study. We sent you a list, of the participating patients with
an ID number of drug class where there may be a concern.
 What did you do with this information?
 What would be helpful for you?
 What would the ideal process look like to you?
 Overall, what was your experience of taking part in
this study?
Concluding comments
 Anything participant would like to add/any
questions for me?
Topic guide – patient
Broad medication-related interview questions
Could you tell me a little about your medications?
Prompts: what do you take; how many medicines; are
your medicines important/necessary; why do you take
them; are there any side effects?
Could you tell me how you feel about taking these
medications?
Prompts: how does having to take your medicines im-
pact on you?
Could you tell me a little about your interactions with
your GP?
Prompts: how often do you see them; what do you dis-
cuss about your medications; what type of information
about your medications do you get?
The intervention - you met with your GP to discuss
some of your medications in a medicines review
 Can you tell me how you found that experience?
○ Informative, beneficial, helpful/unhelpful, negative
 Can you tell me more about why you feel that?
○ How did it differ from your general GP visits?
▪ Get anything extra from it (PIL)?
 Yes – was it useful/informative
 No – would you like something like this?
○ What was the outcome if you don’t mind
discussing it?
 Did anything change (e.g. stopped medication,
reduced dose)?
 Do you think having a review like this, maybe once
or twice a year would be useful?
○ To you, to others etc.
 Elements that may benefit from change
○ Was there anything you disliked – a process
you would like to change?
 How would you describe the experience of taking
part in this study?
○ Positive, negative, useful, neutral etc.
 Effects of intervention overall
▪ In summary, given your experience of the review,
is it something you would be happy to do again
(hypothetically) if your GP asked, would you like
to see it become a routine thing?
Nothing
• Can I ask what you thought of the
information i.e. – vague, not useful etc
• What would have made it more
useful to you i.e. – more detail on
exact issue, alternative advice etc?
Something
• Details of what they did
• Why that course of action?
• Would it be possible/feasible to
do this for all their patients?
Probes:
In what way? Can I ask why/how? Really?
YES
• How do you feel about those
changes – were they positive,
what impact have they had on
you/health/life?
• Are you happy?
NO
• What was the reason for that – your
preference, hospital, no alternative?
• Are you happy with the outcome
generally?
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Appendix 4
Abbreviations
CME, continuing medical education; GMS, General Medical Services; GP,
General Practitioner; HRB, Health Research Board; ICGP, Irish College of
General Practitioners; OPTI-SCRIPT, OPTImizing PreSCRIbing for Older People
in Primary Care, a clusTer randomised controlled trial; PILs, patient information
leaflets; PIP, potentially inappropriate prescribing; RCT, randomised controlled
trial
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